I'm buying Relypsa (RLYP). Their drug was approved last week and stock dropped because of some misinterpretation regarding the label. Current market cap is about $600m, stock is trading at $16 and all analyst price targets are at least $36. Even though the drug was approved, launch is in Jan. There is a competitor coming, but I think Relypsa has a better side effect profile.
I think the stock can easily go to $32. The low was last Thursday just under $12 and it was trading about $20 around mid-Oct.
I think the stock can easily go to $32. The low was last Thursday just under $12 and it was trading about $20 around mid-Oct.